Immunic (NASDAQ:IMUX) Now Covered by B. Riley

B. Riley began coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $6.00 price objective on the stock. B. Riley also issued estimates for Immunic’s Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.24) EPS, […]

Leave a Reply

Your email address will not be published.

Previous post Ecolab Inc. (NYSE:ECL) Shares Acquired by Signaturefd LLC
Next post Redburn Atlantic Begins Coverage on Blackstone (NYSE:BX)